Treatment Response with Ca-125 in Ovarian Cancer Patients: Comparison among RECIST, WHO, Tridimensional and 3D Volumetric Criteria

被引：0
|
作者：
Oliveira, G. [1 ]
Zondervan, R. [2 ]
Harris, G. [2 ]
Hodge, S. [2 ]
Harisinghani, M. [2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2009年 / 192卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical (WHO) and serum tumor marker (CA125) response to platinum based chemotherapy after treatment with paclitaxel in patients with ovarian cancer (OVCA)
    Vermorken, JB
    Huijskes, RVHP
    Hoekman, K
    Burger, CW
    Verheijen, RHM
    Heitbrink, MA
    Pinedo, HM
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 517 - 517
  • [42] Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
    Elham O Hamed
    Hydi Ahmed
    Osama B Sedeek
    Abeer M Mohammed
    Ali A Abd-Alla
    Hazem M Abdel Ghaffar
    Diagnostic Pathology, 8
  • [43] Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
    Hamed, Elham O.
    Ahmed, Hydi
    Sedeek, Osama B.
    Mohammed, Abeer M.
    Abd-Alla, Ali A.
    Ghaffar, Hazem M. Abdel
    DIAGNOSTIC PATHOLOGY, 2013, 8
  • [44] Improving communication and decision making about treatment options for asymptomatic ovarian cancer patients with rising CA-125: The development and pilot of a decision aid
    Juraskova, Ilona
    Anderson, Caroline
    Harrison, James
    Carter, Jonathan
    PSYCHO-ONCOLOGY, 2008, 17 : S229 - S229
  • [45] Predictive treatment response models for epithelial ovarian cancer: Comparison of 2D, 3D, and in vivo models.
    Nourmoussavi, Melica
    Carmona, Euridice
    Mes-Masson, Anne-Marie
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 121 - 121
  • [46] THE PROGNOSTIC-SIGNIFICANCE OF CA-125 HALF-LIFE IN PATIENTS WITH OVARIAN-CANCER WHO HAVE RECEIVED PRIMARY CHEMOTHERAPY AFTER SURGICAL CYTOREDUCTION
    HUNTER, VJ
    DALY, L
    HELMS, M
    SOPER, JT
    BERCHUCK, A
    CLARKEPEARSON, DL
    BAST, RC
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (04) : 1164 - 1167
  • [47] Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
    Tjokrowidjaja, Angelina
    Lee, Chee K.
    Friedlander, Michael
    Gebski, Val
    Gladieff, Laurence
    Ledermann, Jonathan
    Penson, Richard
    Oza, Amit
    Korach, Jacob
    Huzarski, Tomasz
    Manso, Luis
    Pisano, Carmela
    Asher, Rebecca
    Lord, Sarah J.
    Kim, Se Ik
    Lee, Jung-Yun
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Fujiwara, Keiichi
    Sonke, Gabe
    Vergote, Ignace
    Kim, Jae-Weon
    Pujade-Lauraine, Eric
    EUROPEAN JOURNAL OF CANCER, 2020, 139 : 59 - 67
  • [48] Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.
    Tjokrowidjaja, Angelina
    Lee, Chee Khoon
    Friedlander, Michael
    Gebski, Val
    Gladieff, Laurence
    Ledermann, Jonathan A.
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Manso, Luis
    Pisano, Carmela
    Asher, Rebecca
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Fujiwara, Keiichi
    Sonke, Gabe S.
    Vergote, Ignace
    Kim, Jae-Weon
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-A trial of the PMH Phase II Consortium
    Welch, S.
    Hirte, H.
    Elit, L.
    Schilder, R. J.
    Pond, G.
    Kovacs, J.
    Wright, J.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
    Colombo, N.
    Gantzer, J.
    Ataseven, B.
    Cropet, C.
    Scambia, G.
    Herrero, A.
    Sevelda, P.
    Kobayashi, H.
    Vuylsteke, P.
    Mirza, M. R.
    Priou, F.
    Buderath, P.
    Pisano, C.
    Lainez, N.
    Guillemet, C.
    Burges, A.
    Sverdlin, R.
    El-Balat, A.
    Raban, N.
    Ray-Coquard, I. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S614 - S614
12345